Three year naturalistic outcome study of panic disorder patients treated with paroxetine

Dannon, Pinhas N.; Iancu, Iulian; Cohen, A.; Lowengrub, Katherine; Grunhaus, Leon; Kotler, Moshe

doi:10.1186/1471-244x-4-16

“…This issue shall be addressed in a continuation study lasting 3 years and followed by drug discontinuation. During long-term use, SSRIs may cause weight gain and sexual dysfunction, primarily anorgasmia and ejaculatory dysfunction (17,38,39), and benzodiazepine therapy in panic disorder may lead to abuse or misuse and physical dependence, and withdrawal and rebound symptoms when treatment is discontinued (40). Previous reports indicate a high level of relapse following discontinuation of panic disorder pharmacotherapy (6,13,14).…”

Section: Discussionmentioning

confidence: 99%

“…SSRIs have been prescribed for panic disorder with or without agoraphobia for over a decade and are recommended as first-line treatment for panic disorder on the basis of their favorable safety profile (16). The efficacy and safety profile of the SSRI paroxetine has been demonstrated in the treatment of panic disorder in a number of randomized controlled trials (17)(18)(19). However, the benzodiazepines remain one of the most commonly prescribed therapeutic options for panic disorder (20).…”

Section: Introductionmentioning

confidence: 99%

Psychopharmacotherapy of panic disorder: 8-week randomized trial with clonazepam and paroxetine

Nardi¹,

Valença²,

Freire³

et al. 2011

Braz J Med Biol Res

View full text Add to dashboard Cite

“…This issue shall be addressed in a continuation study lasting 3 years and followed by drug discontinuation. During long-term use, SSRIs may cause weight gain and sexual dysfunction, primarily anorgasmia and ejaculatory dysfunction (17,38,39), and benzodiazepine therapy in panic disorder may lead to abuse or misuse and physical dependence, and withdrawal and rebound symptoms when treatment is discontinued (40). Previous reports indicate a high level of relapse following discontinuation of panic disorder pharmacotherapy (6,13,14).…”

Section: Discussionmentioning

confidence: 99%

“…A comparative study of longer duration would also prove valuable. Both clonazepam (11) and paroxetine (17,31) have been shown to be effective in the treatment of panic disorder over long follow-up periods in separate trials. In a naturalistic 3-year study of 67 patients with panic disorder, clonazepam had a sustained therapeutic effect over the entire treatment period (11).…”

Section: Discussionmentioning

confidence: 99%

“…SSRIs have been prescribed for panic disorder with or without agoraphobia for over a decade and are recommended as first-line treatment for panic disorder on the basis of their favorable safety profile (16). The efficacy and safety profile of the SSRI paroxetine has been demonstrated in the treatment of panic disorder in a number of randomized controlled trials (17)(18)(19). However, the benzodiazepines remain one of the most commonly prescribed therapeutic options for panic disorder (20).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Psychopharmacotherapy of panic disorder: 8-week randomized trial with clonazepam and paroxetine

Nardi¹,

Valença²,

Freire³

et al. 2011

Braz J Med Biol Res

View full text Add to dashboard Cite

Selective serotonin reuptake inhibitors, post‐treatment sexual dysfunction and persistent genital arousal disorder: A systematic review

Tarchi,

Merola,

Baccaredda‐Boy

et al. 2023

Pharmacoepidemiology and Drug

5

0

View full text Add to dashboard Cite

PurposeAdverse effects of selective serotonin reuptake inhibitors (SSRIs) on sexual function have been an important area of research for many years. However, the duration of SSRI‐associated sexual adverse effects, and their possible persistence after treatment discontinuation, is still uncertain. The aims of the current systematic review were first to identify existing evidence of sexual dysfunction following SSRI discontinuation, and to provide an account of reported symptoms and proposed treatment options; and second, to establish whether current literature allows accurate estimates of the prevalence of such sexual dysfunction.MethodsA systematic review was conducted on PubMed, Embase, and Google Scholar; papers with clinical data regarding patients with persistent sexual dysfunction after SSRI treatment suspension were included.ResultsOverall, two retrospective interventional studies, six observational studies and 11 case reports were judged eligible for inclusion. It was not possible to determine reliable estimates of prevalence. Similarly, a cause‐effect relationship between SSRI exposure and persistent sexual impairment could not be ascertained. Nonetheless, the potential for continued sexual disturbances despite discontinuation could not be entirely ruled out.ConclusionsThere is a need to investigate a possible dose–response relationship between SSRI exposure and persistent sexual adverse effects. Treatment options for persistent dysfunctions remain limited, but novel therapeutic approaches may be required in order to address an otherwise neglected need for sexual well‐being.

show abstract

Three year naturalistic outcome study of panic disorder patients treated with paroxetine

Abstract: Background: This naturalistic open label follow-up study had three objectives:

Cited by 31 publications

References 20 publications

Psychopharmacotherapy of panic disorder: 8-week randomized trial with clonazepam and paroxetine

Psychopharmacotherapy of panic disorder: 8-week randomized trial with clonazepam and paroxetine

Psychopharmacotherapy of panic disorder: 8-week randomized trial with clonazepam and paroxetine

Selective serotonin reuptake inhibitors, post‐treatment sexual dysfunction and persistent genital arousal disorder: A systematic review

Contact Info

Product

Resources

About